Allergic bronchopulmonary aspergillosis--a clinical review

Allergic bronchopulmonary aspergillosis--a clinical review

Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and rad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Association of Physicians of India 2012-04, Vol.60, p.46-51
Hauptverfasser: Gupta, Rajesh Kumar, Chandr, Amol, Gautam, Praveen Bahadur
Format: Artikel
Sprache:eng
Schlagworte:
Adrenal Cortex Hormones - therapeutic use
Antifungal Agents - therapeutic use
Aspergillosis, Allergic Bronchopulmonary - diagnosis
Aspergillosis, Allergic Bronchopulmonary - drug therapy
Aspergillosis, Allergic Bronchopulmonary - epidemiology
Humans
Itraconazole - therapeutic use
Prognosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 51
container_issue
container_start_page 46
container_title Journal of the Association of Physicians of India
container_volume 60
creator Gupta, Rajesh Kumar
Chandr, Amol
Gautam, Praveen Bahadur
description Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and Itraconazole is now recommended and validated at a dose of 200 mg/day for 16 weeks.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1082406687</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1082406687</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-4555f73c613938190945115f2f95c8a8d1c47af53b0ae0bf4a4a6f17c53b76813</originalsourceid><addsrcrecordid>eNo1j0tLAzEcxHNQbG39CrJHL4G8H95K8QUFL_a8_DdNNJLdrElX8du7Yj0NzPyYYc7QkhAisNSaLdBlre-EcMs5u0ALxgmzWrAlut2k5MtrdE1X8uDe8jilPg9Qvhuo42-SUq6xYgyNS3GIDlJT_Gf0X2t0HiBVf3XSFdrf371sH_Hu-eFpu9nhkTJ1xEJKGTR3is7rhlpihaRUBhasdAbMgTqhIUjeEfCkCwIEqEC1mx2tDOUrdPPXO5b8Mfl6bPtYnU8JBp-n2lJimCBKGT2j1yd06np_aMcS-_lK-_-X_wAOeE-V</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1082406687</pqid></control><display><type>article</type><title>Allergic bronchopulmonary aspergillosis--a clinical review</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gupta, Rajesh Kumar ; Chandr, Amol ; Gautam, Praveen Bahadur</creator><creatorcontrib>Gupta, Rajesh Kumar ; Chandr, Amol ; Gautam, Praveen Bahadur</creatorcontrib><description>Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and Itraconazole is now recommended and validated at a dose of 200 mg/day for 16 weeks.</description><identifier>ISSN: 0004-5772</identifier><identifier>PMID: 23029742</identifier><language>eng</language><publisher>India</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Antifungal Agents - therapeutic use ; Aspergillosis, Allergic Bronchopulmonary - diagnosis ; Aspergillosis, Allergic Bronchopulmonary - drug therapy ; Aspergillosis, Allergic Bronchopulmonary - epidemiology ; Humans ; Itraconazole - therapeutic use ; Prognosis</subject><ispartof>Journal of the Association of Physicians of India, 2012-04, Vol.60, p.46-51</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23029742$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Rajesh Kumar</creatorcontrib><creatorcontrib>Chandr, Amol</creatorcontrib><creatorcontrib>Gautam, Praveen Bahadur</creatorcontrib><title>Allergic bronchopulmonary aspergillosis--a clinical review</title><title>Journal of the Association of Physicians of India</title><addtitle>J Assoc Physicians India</addtitle><description>Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and Itraconazole is now recommended and validated at a dose of 200 mg/day for 16 weeks.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Aspergillosis, Allergic Bronchopulmonary - diagnosis</subject><subject>Aspergillosis, Allergic Bronchopulmonary - drug therapy</subject><subject>Aspergillosis, Allergic Bronchopulmonary - epidemiology</subject><subject>Humans</subject><subject>Itraconazole - therapeutic use</subject><subject>Prognosis</subject><issn>0004-5772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j0tLAzEcxHNQbG39CrJHL4G8H95K8QUFL_a8_DdNNJLdrElX8du7Yj0NzPyYYc7QkhAisNSaLdBlre-EcMs5u0ALxgmzWrAlut2k5MtrdE1X8uDe8jilPg9Qvhuo42-SUq6xYgyNS3GIDlJT_Gf0X2t0HiBVf3XSFdrf371sH_Hu-eFpu9nhkTJ1xEJKGTR3is7rhlpihaRUBhasdAbMgTqhIUjeEfCkCwIEqEC1mx2tDOUrdPPXO5b8Mfl6bPtYnU8JBp-n2lJimCBKGT2j1yd06np_aMcS-_lK-_-X_wAOeE-V</recordid><startdate>201204</startdate><enddate>201204</enddate><creator>Gupta, Rajesh Kumar</creator><creator>Chandr, Amol</creator><creator>Gautam, Praveen Bahadur</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201204</creationdate><title>Allergic bronchopulmonary aspergillosis--a clinical review</title><author>Gupta, Rajesh Kumar ; Chandr, Amol ; Gautam, Praveen Bahadur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-4555f73c613938190945115f2f95c8a8d1c47af53b0ae0bf4a4a6f17c53b76813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Aspergillosis, Allergic Bronchopulmonary - diagnosis</topic><topic>Aspergillosis, Allergic Bronchopulmonary - drug therapy</topic><topic>Aspergillosis, Allergic Bronchopulmonary - epidemiology</topic><topic>Humans</topic><topic>Itraconazole - therapeutic use</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Rajesh Kumar</creatorcontrib><creatorcontrib>Chandr, Amol</creatorcontrib><creatorcontrib>Gautam, Praveen Bahadur</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the Association of Physicians of India</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Rajesh Kumar</au><au>Chandr, Amol</au><au>Gautam, Praveen Bahadur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allergic bronchopulmonary aspergillosis--a clinical review</atitle><jtitle>Journal of the Association of Physicians of India</jtitle><addtitle>J Assoc Physicians India</addtitle><date>2012-04</date><risdate>2012</risdate><volume>60</volume><spage>46</spage><epage>51</epage><pages>46-51</pages><issn>0004-5772</issn><abstract>Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and Itraconazole is now recommended and validated at a dose of 200 mg/day for 16 weeks.</abstract><cop>India</cop><pmid>23029742</pmid><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0004-5772
ispartof Journal of the Association of Physicians of India, 2012-04, Vol.60, p.46-51
issn 0004-5772
language eng
recordid cdi_proquest_miscellaneous_1082406687
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adrenal Cortex Hormones - therapeutic use
Antifungal Agents - therapeutic use
Aspergillosis, Allergic Bronchopulmonary - diagnosis
Aspergillosis, Allergic Bronchopulmonary - drug therapy
Aspergillosis, Allergic Bronchopulmonary - epidemiology
Humans
Itraconazole - therapeutic use
Prognosis
title Allergic bronchopulmonary aspergillosis--a clinical review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A38%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allergic%20bronchopulmonary%20aspergillosis--a%20clinical%20review&rft.jtitle=Journal%20of%20the%20Association%20of%20Physicians%20of%20India&rft.au=Gupta,%20Rajesh%20Kumar&rft.date=2012-04&rft.volume=60&rft.spage=46&rft.epage=51&rft.pages=46-51&rft.issn=0004-5772&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1082406687%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1082406687&rft_id=info:pmid/23029742&rfr_iscdi=true